The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.

Scholz S, Koerber F, Meszaros K, Fassbender RM, Ultsch B, Welte RR, Greiner W (2019)
Vaccine 37(1): 1692-1701.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Autor*in
Scholz, StefanUniBi; Koerber, Florian; Meszaros, Kinga; Fassbender, Rosa Maya; Ultsch, Bernhard; Welte, Robert R; Greiner, WolfgangUniBi
Abstract / Bemerkung
INTRODUCTION: Invasive meningococcal disease (IMD) is a severe disease mainly affecting infants and young children. The most common serogroup causing IMD in Germany is the serogroup type B Neisseria meningitidis (MenB). The aim of the present study is to estimate the economic burden of MenB-related IMD in Germany. METHOD: A bottom-up, model-based costing approach has been used to calculate the diagnose- and age-specific yearly lifetime costs of a hypothetical cohort of MenB-related IMD cases. Direct costs contain the treatment cost for the acute phase of the disease, long-term sequelae, costs for rehabilitation, and public health response. Indirect costs are calculated for the human-capital approach and the friction-cost approach considering productivity losses of patients or parents for the acute phase and long-term sequelae. Publicly available databases from the Federal Statistical Office, the SOEP panel data set, literature, and expert opinion were used as data sources. All future costs beyond the reference year of 2015 were discounted at 3%. RESULTS: The total costs for the hypothetical cohort (343 patients) from a societal perspective are €19.6 million (€57,100/IMD case) using the friction-cost approach and €58.8 million (€171,000/IMD case) using the human-capital approach. Direct costs amount to €18.6 million or €54,300 €/case. Sequelae are responsible for 81% of the direct costs/case. DISCUSSION: The elevated costs/MenB-related IMD case reflect the severity of the disease. The total costs are sensitive to the productivity-loss estimation approach applied. MenB is an uncommon but severe disease; The costs/case reflect the severity of the disease and is within the same magnitude as for human papilloma virus infections. The available literature on sequelae is due to the uncommonness limited and heterogeneous.
Erscheinungsjahr
2019
Zeitschriftentitel
Vaccine
Band
37
Ausgabe
1
Seite(n)
1692-1701
ISSN
1873-2518
Page URI
https://pub.uni-bielefeld.de/record/2933691

Zitieren

Scholz S, Koerber F, Meszaros K, et al. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 2019;37(1):1692-1701.
Scholz, S., Koerber, F., Meszaros, K., Fassbender, R. M., Ultsch, B., Welte, R. R., & Greiner, W. (2019). The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine, 37(1), 1692-1701. doi:10.1016/j.vaccine.2019.01.013
Scholz, S., Koerber, F., Meszaros, K., Fassbender, R. M., Ultsch, B., Welte, R. R., and Greiner, W. (2019). The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine 37, 1692-1701.
Scholz, S., et al., 2019. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine, 37(1), p 1692-1701.
S. Scholz, et al., “The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.”, Vaccine, vol. 37, 2019, pp. 1692-1701.
Scholz, S., Koerber, F., Meszaros, K., Fassbender, R.M., Ultsch, B., Welte, R.R., Greiner, W.: The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany. Vaccine. 37, 1692-1701 (2019).
Scholz, Stefan, Koerber, Florian, Meszaros, Kinga, Fassbender, Rosa Maya, Ultsch, Bernhard, Welte, Robert R, and Greiner, Wolfgang. “The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.”. Vaccine 37.1 (2019): 1692-1701.

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 30661834
PubMed | Europe PMC

Suchen in

Google Scholar